General
94 articles in the General category
National Institutes News: NIH-Linked GLP-1 Study Reportedly Slows Aging in Mice
A National Institutes of Health (.gov) item highlighted in national institutes news reports that a GLP-1 drug slowed aging in mice. Early reports suggest the finding adds to the growing research interest in GLP-1 peptides, though human relevance remains unproven. Here is what the report says and what it does not.
5 min readHow to Tell a Legitimate Compounded GLP-1 Provider From a Risky One: Today News
A new USA Today report outlines how patients and researchers can separate legitimate compounded GLP-1 providers from risky operators. The guidance arrives as demand for compounded semaglutide and tirzepatide remains high and quality standards vary widely across the market.
5 min readWegovy News: Oral GLP-1 Tracker Shows Novo and Lilly Prescription Growth
New prescription tracking data suggests oral GLP-1 products from Novo Nordisk and Eli Lilly are gaining traction. The latest Wegovy news points to a shifting market for metabolic research compounds, with researchers watching how oral formulations compare to injectable peptides.
5 min readSemaglutide News: Key Differences Between Semaglutide and Tirzepatide
Semaglutide and tirzepatide are two of the most discussed peptide-based compounds in research and industry circles. This analysis breaks down what each one is, how they differ, and why the distinction matters for researchers tracking the latest semaglutide news in 2026.
5 min readSemaglutide News: New Meta-Analysis Highlights Weight and Inflammatory Benefits
A recent systematic review and meta-analysis examines the effects of subcutaneous semaglutide on weight loss and inflammatory markers in adults with overweight or obesity without diabetes. Early reports suggest meaningful reductions in body weight alongside improvements in inflammatory biomarkers, offering new context for peptide researchers and industry professionals.
7 min readNovo Nordisk Launches Wegovy Weight-Loss Pill in Germany: What It Means
Novo Nordisk has reportedly launched Wegovy, its weight-loss medication, in Germany. This move signals continued expansion of GLP-1-based therapies in Europe and highlights the growing intersection between pharmaceutical weight management and peptide research.
5 min readSemaglutide News: How Long to Lose 30 Pounds on Semaglutide?
A common question in the semaglutide news cycle is how long it takes to lose 30 pounds on the medication. While individual results vary, clinical trial data and prescribing guidelines offer a general timeline. This article breaks down the expected weight loss trajectory and what factors influence the pace.
6 min readSemaglutide News 2026: How to Calculate Peptide Reconstitution
As semaglutide news 2026 continues to generate interest among researchers, understanding how to calculate reconstitution for peptides is essential. This guide covers the math, safety, and practical steps for accurate peptide preparation.
5 min readSemaglutide News 2026: How Much Water to Mix with Peptides?
As semaglutide news 2026 continues to dominate headlines, researchers and biohackers are asking a practical question: how much water to mix with peptides? This article provides a factual overview of peptide reconstitution, including the role of semaglutide and Ozempic, and offers guidance for accurate preparation.
5 min readWegovy News: Oral GLP-1 Tracker Shows Market Share Ceiling for Novo's Pill
Recent Wegovy news suggests Novo Nordisk's oral GLP-1 pill is struggling to break through a market share ceiling, according to industry reports. This analysis explores the implications for peptide researchers and the broader GLP-1 landscape.
5 min read5 Mental Health Benefits of GLP-1 Drugs Like Ozempic and Wegovy: Latest Ozempic News
Recent reports highlight five mental health benefits associated with GLP-1 drugs like Ozempic and Wegovy, extending beyond weight loss. This analysis covers the implications for peptide researchers and the broader industry.
6 min readEli Lilly sues pharmacies over early retatrutide sales: retatrutide news
Eli Lilly is taking legal action against pharmacies and peptide vendors for selling retatrutide before approval. This retatrutide news highlights the growing tension between pharmaceutical IP protection and the peptide research market.
4 min readMounjaro News: GLP-1 Drug May Lower Heart Attack Risk in Type 2 Diabetes
Recent reports suggest that Mounjaro, a GLP-1 receptor agonist for type 2 diabetes, may lower heart attack risk. This analysis explores the news, its potential implications for peptide research, and what it means for the industry.
6 min readOzempic News: New GLP-1 Pill Shows 12% Weight Loss in 36 Weeks
Recent ozempic news highlights a new oral GLP-1 drug that reportedly delivers up to 12% weight loss over 36 weeks. While the specific medication name remains unconfirmed, this development signals continued progress in GLP-1 research. Learn what this means for peptide researchers and industry professionals.
5 min readSemaglutide News: Orthopedic Surgeon Shares Key Insights on Ozempic and Wegovy
Recent semaglutide news highlights an orthopedic surgeon's perspective on Ozempic and Wegovy. The report touches on weight loss efficacy and safety considerations, offering context for researchers and industry professionals tracking GLP-1 developments.
7 min readSupercharged News: How Social Media Is Warping Teen Psyches in the GLP-1 Boom
A recent Bloomberg report highlights how the GLP-1 boom, supercharged by social media, is warping teen psyches. This analysis explores the implications for peptide research and the importance of responsible communication in the digital age.
5 min readOzempic News: GLP-1s May Lower Fracture Risk in Type 2 Diabetes
Recent reports suggest that GLP-1 receptor agonists like Ozempic and Mounjaro may reduce fracture risk in type 2 diabetes patients. While the findings are preliminary, they add to the growing evidence of benefits beyond glucose control. Researchers and industry professionals are watching closely.
5 min readSemaglutide News: Novo Nordisk's GLP-1 Lead Faces New Challenges
Recent semaglutide news highlights how Novo Nordisk's early lead in GLP-1 weight-loss drugs is being tested. This analysis covers the company's position, the science behind semaglutide, and what researchers should watch next.
4 min readSemaglutide News: Novo Nordisk Wins Dutch Patent Injunction
Novo Nordisk has secured a Dutch court injunction in a semaglutide patent infringement case, according to recent reports. The decision adds a layer of legal protection for the drug, which is also marketed as Wegovy. This semaglutide news highlights ongoing efforts to safeguard intellectual property in the growing GLP-1 market.
5 min readTirzepatide News: GLP-1 Drug Demand Surges, MACE Risk May Drop
Recent reports suggest tirzepatide, a GLP-1 drug, may reduce MACE risk in high-risk patients while demand for injectable GLP-1 therapies remains strong. This analysis covers the latest tirzepatide news and its implications for peptide research and clinical practice.
5 min readLilly Beats Estimates as Injectable GLP-1 Demand Stays Strong: Semaglutide News
Eli Lilly exceeded earnings expectations on resilient demand for injectable GLP-1 therapies. As the field looks toward upcoming conferences, semaglutide news and next-gen peptides like retatrutide are shaping the anti-obesity landscape.
5 min readSemaglutide News: Lilly Beats Estimates on Resilient GLP-1 Demand
Eli Lilly reportedly exceeded earnings expectations, driven by sustained demand for injectable GLP-1 therapies. As the obesity treatment market evolves, upcoming conferences are set to showcase next-generation peptides and real-world data, shaping the future of anti-obesity research.
7 min readMembranolytic Peptides Trigger Immunogenic Cell Death in Cancer Treatment
Researchers report that membranolytic peptides can program immunogenic cell death, offering a novel approach to cancer therapy. The strategy leverages the peptides' membrane-disrupting properties to induce a form of cell death that activates an immune response. This finding, published by Nature, highlights a potential new avenue for cancer treatment.
5 min readTirzepatide Enhances Outcomes in Obesity With PsA: Latest Tirzepatide News
Recent reports suggest tirzepatide may enhance outcomes in patients with obesity and psoriatic arthritis. This analysis covers the potential implications for peptide research and clinical practice, while noting the need for further verification.
5 min readSemaglutide News: Peptide Therapy for Erectile Dysfunction Gains Attention
Recent semaglutide news highlights the growing interest in peptide therapy for erectile dysfunction. While early reports suggest potential benefits, researchers emphasize the need for more clinical data. This article explores the current landscape, safety considerations, and what it means for the peptide industry.
5 min readPeptide Therapy for Erectile Dysfunction: Overview and Insights
This article provides an overview of peptide therapy as a potential approach for erectile dysfunction, referencing a specific report titled 'Peptide Therapy for Erectile Dysfunction - View E8bbJ0QKa' from FC Bayern. The report was published on August 2, 2026, and is categorized under General. The article summarizes the key points and context surrounding this topic.
5 min readVeterans Affairs News: GLP-1 Study for Alcohol Disorder Begins
The Department of Veterans Affairs has reportedly launched a study to investigate whether GLP-1 receptor agonists could help treat alcohol use disorder. Early reports suggest the trial will explore a new application for a class of drugs already known for metabolic effects. This article covers the news and its potential implications for peptide research.
6 min readBPC-157 News: FDA Advisers Weigh Easing Restrictions on Six Peptides
FDA advisers have reportedly supported easing restrictions on six peptides, a move that could reshape the peptide research landscape. While BPC-157 and TB-500 were not explicitly named, the decision signals growing regulatory attention. Here's what researchers and industry professionals should know.
5 min readBPC-157 News: Hydreight Updates Peptide Platform After FDA Advisory
Hydreight has issued a business update on its peptide healthcare platform following recent FDA advisory committee recommendations. The update highlights the growing regulatory attention on GLP-1 drugs like Ozempic and Wegovy, and what it means for peptide research and industry stakeholders.
5 min readOral GLP-1 News: Verdiva Bio's VRB-103 Advances to Phase 1 Trials
Verdiva Bio has initiated a Phase 1 study of VRB-103, a selective oral amylin peptide analog with weekly dosing potential. This development highlights the growing interest in oral peptide therapeutics for metabolic conditions, offering researchers new avenues for investigation.
6 min readOrforglipron vs. Tirzepatide: Major Differences in Semaglutide News
This analysis compares orforglipron and tirzepatide, two emerging compounds in the GLP-1 receptor agonist space, against the backdrop of recent semaglutide news. We explore their mechanisms, research status, and potential implications for peptide researchers and industry professionals.
5 min readSemaglutide News: Ozempic and Wegovy May Also Treat Alcohol Use Disorder
A new trial suggests that drugs like Ozempic and Wegovy, known for diabetes and weight loss, may also reduce alcohol cravings in people with alcohol use disorder. This article explores the implications for peptide researchers and the broader pharmaceutical industry, with a focus on the potential repurposing of GLP-1 receptor agonists.
5 min readSandoz Semaglutide News: EMA Approval and Industry Impact
Sandoz has reportedly received regulatory approval for a new semaglutide treatment option, marking a significant development in the peptide therapeutics space. This article analyzes the semaglutide news, the role of the EMA, and implications for researchers and industry professionals.
4 min readDoes Zepbound Increase Metabolism? What Research Says About Tirzepatide and Meta
A recent Forbes article explores whether Zepbound, a brand name for tirzepatide, increases metabolism. This analysis examines the reported mechanisms and implications for peptide researchers and industry professionals, with a focus on metabolic rates and energy expenditure.
5 min readFrequent Contraceptive Switching Tied to Semaglutide Use: What Researchers Should Know
A recent report from Medscape has linked frequent contraceptive switching to the use of semaglutide, the GLP-1 receptor agonist widely prescribed for type 2 diabetes and weight management. Early reports suggest that women using semaglutide may experience changes in contraceptive efficacy or tolerability, prompting more frequent method changes. This article explores the implications for peptide researchers and industry professionals.
5 min readOzempic News: Orthopedic Surgeon Warns Patients About Muscle Loss Risks
Recent ozempic news highlights concerns from an orthopedic surgeon about muscle loss in patients using Ozempic and Wegovy. This analysis explores the implications for peptide researchers and industry professionals, focusing on the balance between weight loss and preserving lean mass.
4 min readObesity Phenotype Predicts Tirzepatide Super Responders: New Insights
Recent research suggests that specific obesity phenotypes may identify individuals who achieve exceptional weight loss with tirzepatide. This article explores the implications for peptide researchers and the broader industry, with a focus on personalized approaches to obesity treatment.
5 min readMedicare Pays Billions For Obesity’s Consequences. Its GLP-1 Coverage Gap
Medicare spends billions treating obesity-related diseases but does not cover GLP-1 receptor agonists for weight loss alone. This analysis explores the financial and clinical implications, including recent developments in triple peptide agonists like ASC37 from Ascletis.
4 min readSemaglutide Benefits Last Beyond First Year, New Study Suggests
A recent study indicates that the benefits of semaglutide, the active ingredient in Ozempic and Wegovy, may persist beyond the first year of use. The findings offer new insights for researchers and clinicians monitoring long-term patient outcomes with this GLP-1 receptor agonist.
5 min readSemaglutide News: A Case of Severe Hypercalcemia in a Patient Taking Tirzepatide
A recent case report has highlighted a potential risk factor for patients taking tirzepatide: severe hypercalcemia. This semaglutide news analysis explores the reported incident, possible mechanisms, and implications for peptide researchers and clinicians, emphasizing the need for careful monitoring of electrolyte imbalances in GLP-1 receptor agonist therapies.
4 min readOzempic News: GLP-1 Drugs Offer Value but Risk Budget Overload and Safety Concerns
Ozempic, Wegovy, and Zepbound show strong health value, but covering millions of eligible patients could overwhelm insurance budgets. Researchers call for better long-term support and warn that low-cost compounded versions carry serious safety risks.
5 min readFDA Panel Votes to Loosen Regulations on Peptides Including Tesamorelin News
An FDA advisory committee has voted to recommend easing restrictions on four peptides, including BPC-157, TB-500, and reportedly tesamorelin, despite opposition from the agency's own scientists. This decision could reshape the regulatory landscape for peptide research and access.
5 min readFDA Panel Supports Lifting Restrictions on Tesamorelin and Other Peptides
An FDA advisory panel has recommended easing restrictions on four peptides, including tesamorelin and BPC-157, despite objections from some scientists. The decision could widen access to these research compounds, sparking debate among researchers, biohackers, and industry professionals.
5 min readOzempic News 2026: Swiss Firm Links Botox Boom to 'Sagging Face' Trend
A Swiss pharmaceutical firm reports that the popularity of Ozempic and similar GLP-1 drugs is boosting demand for Botox and other aesthetic procedures, as patients seek to address facial volume loss often associated with rapid weight loss. This ozempic news 2026 trend highlights the growing intersection of metabolic and aesthetic medicine.
5 min readGLP-1 Drugs and Ozempic Face: Is It Changing Aesthetic Care?
A new discussion in aesthetic medicine explores whether GLP-1 drugs like Ozempic are reshaping patient expectations and care standards. This article summarizes the emerging conversation, with hedging on unverified claims, and provides context for peptide researchers and industry professionals.
6 min readSemaglutide Sustains Lower Calorie Intake for More Than a Year, Study Shows
A new study indicates that semaglutide, a GLP-1 receptor agonist, can sustain reduced calorie intake for over a year. This analysis explores the findings, their implications for peptide research, and the broader industry context, including regulatory perspectives from the FDA and EMA.
5 min readCompounded Ozempic and Zepbound Still Widely Available Despite End of Drug Shortage
Despite the FDA declaring an end to shortages of Ozempic and Zepbound, compounded versions remain widely accessible. This analysis explores the regulatory landscape, the role of major players like Novo Nordisk and Eli Lilly, and what this means for peptide researchers and industry professionals.
4 min readFDA’s Review Of Peptides Signals A Growing Public Health Challenge
The FDA’s review of peptides highlights a growing public health challenge as unregulated products flood the market. This analysis separates science from hype, offering context for researchers and industry professionals navigating the evolving regulatory landscape.
4 min readSouth Africa Regulator Reviews 12 Generic Semaglutide Applications: Semaglutide News
South Africa's health regulator is reviewing 12 applications for generic semaglutide, a development with significant implications for global peptide research and access. This semaglutide news highlights the growing demand for affordable GLP-1 receptor agonists and the evolving regulatory landscape.
4 min readSamsung Biologics Acquires PolyPeptide: Semaglutide News and Industry Impact
Samsung Biologics has proposed a $1.8 billion acquisition of Swiss CDMO PolyPeptide, signaling major growth in peptide manufacturing. This semaglutide news highlights the expanding role of contract development and manufacturing organizations in meeting rising demand for GLP-1 receptor agonists like semaglutide.
4 min readFDA Conflict of Interest Concerns Ahead of Peptide Panel: Melanotan News Update
The FDA has raised conflict of interest concerns ahead of a new peptide advisory panel, according to recent reports. This development has implications for the peptide industry, including ongoing discussions around melanotan and other research compounds. Learn what this means for researchers and industry professionals.
5 min readSemaglutide vs Tirzepatide: Key Differences in Peptide Research
Semaglutide and tirzepatide are both GLP-1 receptor agonists but differ in mechanism, efficacy, and clinical applications. This article compares their molecular targets, research outcomes, and safety profiles for researchers and industry professionals.
5 min readSemaglutide News: Case Report on Refractory Reactive Hypoglycaemia Treatment
A recent case report explores the use of semaglutide for refractory reactive hypoglycaemia, a condition where blood sugar drops after meals. This semaglutide news highlights potential new applications for the GLP-1 receptor agonist, though researchers urge caution until larger studies confirm efficacy and safety.
5 min readOzempic News: GLP-1 Drugs Like Ozempic and Wegovy May Help Treat Binge Eating Disorder
Recent reports suggest that GLP-1 receptor agonists, including Ozempic and Wegovy, may offer therapeutic potential for binge eating disorder. This article explores the implications for peptide researchers and the broader industry, with a focus on the science behind these medications.
4 min readOzempic News: Wegovy Tablet Launch in Europe and Hidden Brain Disorder Risks
Novo Nordisk reportedly plans to launch a tablet version of Wegovy in Europe, expanding access to GLP-1 therapies. Meanwhile, doctors have identified a hidden danger for some Ozempic and Wegovy users with brain disorders, raising safety concerns. This article analyzes the latest developments with peptide industry context.
4 min readEU Approves Wegovy Pill for Weight Loss: What Researchers Need to Know
The European Union has reportedly approved a pill form of Wegovy for weight loss, marking a potential shift in obesity treatment. This article explores the news, its implications for peptide researchers, and what it means for the industry.
4 min readEarly Antimicrobial Peptide Maturation Linked to Host-Pathogen Coexistence: Ozempic News Context
A new study published in Nature reveals that early maturation of host antimicrobial peptide defenses is associated with host-pathogen coexistence. This finding has implications for peptide research and drug development, with the FDA monitoring related safety signals. The article provides peptide industry context and discusses how this research aligns with broader trends in antimicrobial peptide therapies.
5 min readCompounders News: How Compounding Pharmacies Maintain GLP-1 Market Grip
Compounding pharmacies continue to hold a strong position in the GLP-1 market, according to recent industry analysis. This article examines the factors behind their sustained influence and what it means for peptide researchers and industry professionals.
3 min readUnderstanding Research Peptides vs. Pharmaceutical Peptides: BPC-157 News
This article explains the key differences between research peptides and pharmaceutical-grade peptides, with a focus on BPC-157. It covers regulatory status, purity standards, and intended use, providing clarity for researchers and industry professionals.
5 min readNovo Secures European Approval for Oral Wegovy: Ozempic News and Industry Impact
Novo Nordisk has reportedly secured European approval for an oral formulation of Wegovy, a move that could extend its lead over rival Eli Lilly in the GLP-1 receptor agonist market. This ozempic news update explores the implications for peptide researchers and the broader industry.
5 min readDoctors Warn of Hidden Danger for Ozempic and Wegovy Users With Brain Disorders
Recent reports from Fox News indicate that doctors are alerting to a potential hidden danger for individuals using Ozempic or Wegovy who have underlying brain disorders. While the details remain unconfirmed, the news underscores the importance of careful medical oversight for patients on GLP-1 receptor agonists. This article explores the reported concerns and their implications for peptide research and clinical practice.
4 min readSemaglutide News: Dr. Reddy’s Reports Shipping Disruption Until Late October
India’s Dr. Reddy’s Laboratories has announced a disruption in semaglutide shipments expected to last until at least late October 2025. The news affects researchers and patients relying on steady supply of this GLP-1 receptor agonist, commonly known as Ozempic. This analysis covers the implications for the peptide industry.
4 min readNovo Nordisk Updates Wegovy Label in Singapore With STEP UP Data: What It Means for Peptide Research
Novo Nordisk (NYSE:NVO) has reportedly updated the Wegovy label in Singapore following data from the STEP UP clinical trial. This analysis explores the implications for peptide researchers and the broader GLP-1 receptor agonist landscape, with a focus on safety, efficacy, and future research directions.
5 min readWhat Older Adults Should Know About GLP: Semaglutide News and Pancreatic Cancer Research
Recent developments in peptide research include a novel approach to pancreatic cancer treatment announced by Neo7Bioscience. This article explores what older adults should know about GLP-related therapies, including semaglutide news, and how precision signal interception may offer new hope beyond conventional RAS pathway suppression.
4 min readSemaglutide News: Poison Control Calls Spike Due to Dosing Errors
Poison control calls involving semaglutide (Ozempic and Wegovy) have surged after the drug was approved for weight management. Researchers attribute the increase to accidental dosing mistakes, not intentional misuse, highlighting the need for better patient education on weekly dosing and gradual dose escalation.
4 min readHealthy Returns News: Employers Not Expanding GLP-1 Obesity Drug Coverage
Recent healthy returns news suggests employers are not expanding coverage of GLP-1 obesity drugs, despite rising demand. This analysis explores the implications for the peptide industry, including regulatory context from the FDA and market shifts involving companies like Hims & Hers.
5 min readAmericans Are Taking GLP-1 Drugs in Record Numbers: Ozempic News Analysis
Recent reports indicate that Americans are taking GLP-1 receptor agonists like Ozempic and Wegovy in record numbers, reshaping the weight loss drug landscape. This analysis explores the implications for peptide research and manufacturing, including a new cGMP agreement that underscores industry growth.
4 min readSecret News: Secret Shopper Study Probes GLP-1 Telehealth Sites
A recent secret shopper study reportedly investigated GLP-1 telehealth sites, raising questions about prescribing practices and patient safety. This analysis explores the implications for peptide researchers and industry professionals.
4 min readSome Sleep Apnea Patients Benefit the Most From Tirzepatide News
Recent reports suggest that some sleep apnea patients may benefit significantly from tirzepatide, a drug originally developed for type 2 diabetes. This analysis explores the potential implications for peptide researchers and industry professionals, with a focus on the evolving role of tirzepatide in metabolic and sleep disorder research.
4 min readSemaglutide News: Kidney Protection and Survival Benefits by CKD Severity in FLOW Trial
Recent analyses from the FLOW trial suggest semaglutide may offer kidney protection and improve survival outcomes across varying stages of chronic kidney disease. This article examines the reported findings and their implications for peptide research and therapeutic development.
5 min readMounjaro News: Generic GLP-1 Drugs May Soon Be Available
Recent reports suggest that generic versions of popular GLP-1 drugs, including Mounjaro and Zepbound, may become available sooner than expected. This article analyzes the potential impact on the peptide research industry and what researchers should know.
3 min readWegovy Weight Loss Pill Now Available on UK High Street: What Researchers Need to Know
The Wegovy weight loss pill has officially gone on sale in UK high street and online pharmacies, marking a significant milestone in obesity treatment. This article provides an analysis of the news, its implications for the peptide industry, and answers key questions about Wegovy's safety and side effects for researchers and professionals.
6 min readDoes Semaglutide Increase Your Metabolism? What Experts Say
A recent Forbes report explores whether semaglutide, the popular GLP-1 receptor agonist, directly increases metabolism. While early findings suggest potential metabolic effects beyond appetite suppression, experts urge caution. This article analyzes the latest semaglutide news and its implications for peptide researchers and industry professionals.
5 min readNovo Nordisk Wins UK Wegovy Pill Approval as Medicare Opens GLP 1 Access: Semaglutide News
Novo Nordisk reportedly secures UK approval for an oral Wegovy formulation, while Medicare expands GLP-1 coverage for obesity. This analysis covers the implications for peptide researchers and the broader industry, with a focus on the evolving regulatory and access landscape for semaglutide-based therapies.
5 min readNew Biweekly GLP-1 Shot Lowers Blood Sugar, Supports Weight Loss: Semaglutide News Update
A new biweekly GLP-1 shot reportedly lowers blood sugar and supports weight loss, according to early reports. This semaglutide news update examines the potential implications for peptide researchers and industry professionals, with a focus on Ozempic and Wegovy.
5 min readWhy breakthrough GLP-1 weight loss pills may challenge employer insurance coverage
Recent reports suggest that the arrival of oral GLP-1 weight loss pills could create unexpected hurdles for employer-sponsored insurance coverage. This analysis explores the potential implications for the peptide industry, researchers, and biohackers.
4 min readWhat's Next for GLP-1 Weight Loss Drugs: Industry Analysis and Peptide Context
The future of GLP-1 receptor agonists in weight management is a hot topic in peptide research. This article explores the latest developments, including next-generation compounds, oral formulations, and combination therapies, while providing context for peptide researchers and industry professionals.
5 min readSemaglutide News: Ozempic Linked to Fewer Bone Fractures Despite Greater Weight Loss
Recent data presented at the American Diabetes Association annual meeting suggests semaglutide (Ozempic, Wegovy) may reduce bone fracture risk even with significant weight loss. This semaglutide news adds a new dimension to GLP-1 research, with implications for metabolic and skeletal health.
4 min readSemaglutide News: Ozempic Linked to Fewer Bone Fractures Despite Greater Weight Loss
New data presented at the American Diabetes Association annual meeting suggests semaglutide (Ozempic, Wegovy) may reduce bone fracture risk, even with significant weight loss. The findings add a new layer to the safety profile of GLP-1 receptor agonists and have implications for peptide research.
5 min readZepbound News: Why Setting Weight Loss Goals May Be Key to Success
Recent reports suggest that setting structured weight loss goals could be critical for success with Zepbound. This analysis explores the implications for peptide researchers and industry professionals, while contextualizing the drug within broader peptide science.
3 min readFDA Targets Telehealth Companies Over Compounded Semaglutide Claims
The US FDA sent 25 warning letters to telehealth companies regarding misleading claims about compounded weight-loss drugs, including semaglutide. This action highlights regulatory concerns over the promotion of unapproved versions of drugs like Ozempic and Wegovy. The news carries implications for peptide researchers and the broader industry.
4 min readZepbound News: Why Setting Weight Loss Goals May Be Key to Success
Recent reports suggest that setting structured weight loss goals may improve outcomes with Zepbound. This analysis explores the potential role of goal-setting in peptide-based weight management, offering context for researchers and industry professionals.
3 min readFDA Cracks Down on Telehealth Claims for Compounded Weight-Loss Drugs
The US FDA sent 25 warning letters to telehealth companies over unsubstantiated claims about compounded semaglutide and other weight-loss drugs. This action highlights regulatory scrutiny in the peptide and GLP-1 space, with implications for researchers and industry professionals.
4 min readRugiet enters longevity market with peptide therapy offerings
Rugiet has announced its expansion into the longevity sector by offering peptide therapies. The move marks a strategic shift for the company, which previously focused on other health areas. The new peptide-based treatments are designed to address age-related health concerns.
2 min read
Brain-Protecting Peptide Discovery May Shift Parkinson’s Treatment
Scientists have identified a peptide that protects brain cells, potentially altering how Parkinson’s disease is treated. The discovery, reported by SciTechDaily on June 17, 2026, highlights a new avenue for slowing neurodegeneration. The peptide’s protective effects could lead to therapies that target the underlying causes of Parkinson’s rather than just symptoms.
2 min readRugiet Launches Peptide and Longevity Therapies: Ozempic News Context
Rugiet has launched a new line of physician-prescribed peptide and longevity therapies, setting a standard for performance medicine. This development comes amid ongoing ozempic news and interest in weight management drugs like Wegovy. The article explores the implications for peptide researchers and industry professionals.
4 min readPharmacy Guidance on GLP-1s and Compounded Peptide Therapies
Pharmacy Times published guidance for pharmacists on counseling patients about GLP-1 receptor agonists and compounded peptide therapies. The article covers what patients want to know about these treatments, including safety, efficacy, and regulatory considerations.
2 min readGLP-1 Receptor Agonist Use After Liver Transplant: Case Report
A case report on glucagon-like peptide-1 (GLP-1) receptor agonist treatment following liver transplantation appears in Cureus. Described as hypothesis-generating, the report presents observations from a specific patient case. Publication occurred on May 13, 2026.
1 min read
Functional Peptide Screening Advances for GPCRs and Radiopharma
Pharmaceutical companies show increased focus on G protein-coupled receptors and radioligand therapies, highlighting functional peptide screening platforms. Eli Lilly paid $140 million upfront to Radionetics Oncology in July 2024 for access to novel GPCR targets, with an option to acquire for $1 billion. These platforms help identify agonists that activate signaling pathways, setting them apart in drug discovery.
3 min readPrecision Peptide CSO Justin Kirkland on Human Upgrade with Dave Asprey
Justin Kirkland serves as Chief Scientific Officer at The Precision Peptide Company. He will be featured on The Human Upgrade with Dave Asprey. This guest appearance places the company executive on the show hosted by Dave Asprey. Kirkland's role leads to this program feature.
2 min readNature Publishes on Evolving Obesity Pharmacotherapy
Nature published an article titled 'The evolving landscape of obesity pharmacotherapy' on 2026-05-13T21:47:07.000Z. This release comes from the journal Nature. The piece falls into the general category.
1 min readStephanie Lueras on Peptide Therapies: Promise, Precautions, Safety
Stephanie Lueras addresses peptide therapies, their promise, precautions, and patient safety. She covers these elements in a focused discussion. Key aspects include potential benefits alongside safety measures.
1 min readLüt Partners with APA and AIVA for Compliant Peptide Payments
Lüt has announced a partnership with the American Peptide Association (APA) and American IV Association (AIVA). The collaboration aims to provide compliant payments for the peptide and wellness industries. This news comes from Business Wire on 2026-05-05.
1 min readECRI and ISMP Warn Patients Lack Reliable Wellness Peptide Safety Data
ECRI and ISMP caution that patients using wellness peptides have no reliable information on their safety or effectiveness. This warning highlights a key gap in available data for these products. The alert comes from a StreetInsider report dated May 5, 2026.
2 min readOther categories